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Abstract
Type 1 diabetes (T1D) results from the autoimmune destruction of the insulin-producing 
-cells. As a result, people with T1D suffer from high blood glucose which 
requires exogenous insulin therapy to maintain within the normal physiological range. 
However, exogenous insulin therapy does not mimic the tightly regulated function of the 
pancreas, and as a result does not prevent the development of diabetic complications. 
Currently, the only cure is either pancreas or islet transplantation; however these treatments 
are hampered by a shortage of donors. As a result, the generation of an alternative cell 
replacement therapy would overcome the aforementioned limitations with current treatments. 
Gene therapy as a means of generating “artificial” insulin-producing cells (IPCs) is being 
considered as a potential cure for T1D. Previous research has shown that the viral-mediated 
transfer of the pancreatic transcription factor NeuroD1 and human furin-cleavable insulin
(INS-FUR) genes to hepatocytes resulted in their transdifferentiation into pancreatic-like cells 
capable of synthesising, storing and secreting insulin in response to fluctuating glucose 
concentrations. Due to their ease of isolation, ease of genetic modification and immune-
modulatory properties, the aim of this study was to evaluate the utility of ex vivo expanded 
murine bone marrow-derived mesenchymal stem cells (BMSCs) as gene therapy targets for 
the development of a T1D cell replacement therapy following the lentiviral over-expression 
of murine NeuroD1 and Pdx1, and INS-FUR.
Non-invasive bioluminescence imaging (BLI) technology is an established and sensitive tool
for accessing cell replacement therapy efficacy and treatment outcome in living preclinical 
small animal models. Furthermore, preclinical BLI results often serve as the decision point of 
a cell replacement therapy’s suitability (efficacy and safety) for clinical trial testing in 
humans.  This study utilised the Firefly luciferase reporter protein Luc2, a Luc2 specific light 
producing substrate D-luciferin and an IVIS Lumina II imaging system. First, a unique sub-
population of BMSCs were isolated from the bone marrow of non-obese diabetic (NOD)
mice. These BMSCs displayed potent clonogenicity and tri-lineage differentiation potential,
hallmark characteristics of mesenchymal stem cells, when compared to the plastic adherent 
bone marrow stromal cell starting population. Second, BMSCs were nucleofected to express
the yeast fusion cytosine deaminase uracil phosphoribosyltransferase (CDUPRT) and/or Luc2
genes (BMSC-Luc2/CDUPRT; BMSC-Luc2). Luc2 was utilised as a reporter protein for 
evaluating the in vitro and in vivo persistence of transgene expression in BMSCs and the in 
vivo persistence of gene-modified BMSCs in immune intact and immune-compromised mice. 
CDUPRT is a pro-drug converting enzyme, otherwise known as a suicide gene that was 
utilised as a cell therapy experimental ‘off’ switch. CDUPRT converts the non-toxic pro-drug 
5-fluorocytosine (5-FC) into the toxic metabolite 5-fluorouracil (5-FU) that causes BMSC
death. In vitro functional characterisation of CDUPRT using a Luc2 based cytotoxicity assay 
showed that following exposure to 5-FC, BMSC-Luc2/CDUPRT demonstrated increased cell 
death when compared to BMSC-Luc2 and parental BMSC controls. A subcutaneous 
transplant of Luc2/CDUPRT-expressing BMSCs in immune-intact (NOD; n=4) and immune-
deficient (NOD/Scid; n=4) mice persisted for 2 weeks and 12 weeks respectively. These 
results show a BMSC transplant survival providing an experimental window of 12 weeks in 
NOD/Scid mice and the rapid immune-mediated destruction of BMSC carrying non-
mammalian genes in NOD mice.
Ex vivo culture-expanded BMSCs were subsequently transduced with the HMD lentiviral 
vector (MOI=10) to express INS-FUR, and murine NeuroD1 and Pdx1 as m -cell 
differentiation. Pancreatic transdifferentiation was characterised via reverse transcriptase 
polymerase chain reaction (RT-PCR), followed by the assessment of insulin storage and 
secretion. INS-FUR-expressing BMSCs lacked glucose-responsiveness and secreted large 
amounts of human insulin chronically, whereas NeuroD1 and Pdx1-expressing BMSCs 
lacked glucose-responsiveness and insulin secretion capabilities. Furthermore, RT-PCR 
analysis showed that BMSC did not undergo pancreatic transdifferentiation when transduced 
with pancreatic transcription factors, and did not store insulin within secretory granules as 
determined by acid/ethanol extraction. A subcutaneous transplant of 1x107 and 5x107 INS-
FUR-expressing BMSCs were assessed for their ability to reverse diabetes in STZ-NOD/Scid
mice (n=5), which failed to do so upon transplantation.
This study showed ex vivo expanded BMSC multipotential differentiation into fat and bone
diminishes with increasing passage, and therefore BMSC may be more useful as gene therapy 
targets prior to expansion. This correlates with other studies where ex vivo expansion of 
MSCs is associated with a loss of MSC characteristics (phenotype, proliferative capacity, 
self-renewal, immunomodulation) and negative T1D clinical outcomes.
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AD-MSCs Adipose-derived mesenchymal stem cells
ANOVA Analysis of variance
APC Antigen presenting cell
ATP Adenosine triphosphate
BB Biobreeding
bFGF Basic fibroblast growth factor
BLI Bioluminescence imaging
BMSCs Bone marrow-derived mesenchymal stem cells
CD Cluster of differentiation
CD Cytosine deaminase
CDUPRT Yeast cytosine deaminase uracil phosphoribosyltransferase fusion pro-
drug converting enzyme
CLEC16A C-type lectin domain containing 16A
CMV Cytomegalovirus
CRISPR Clustered regularly interspaced short palindromic repeat





eGFP Enhanced green fluorescent protein
EGR1 Early growth response-1
ER Endoplasmic reticulum
ESCs Embryonic stem cells
ESRF End-stage renal failure
FACS Fluorescence-assisted cytometric sorting
FCS Foetal calf serum
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G1RE Glucose-responsive element
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GFP Green fluorescent protein
GLUT2 Glucose transporter 2
GSIS Glucose-stimulated insulin secretion
GWAS Genome-wide association study
HbA1C Glycated haemoglobin
HBSS Hanks buffered salt solution
HDAD Helper-dependent adenovirus
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hIPCs Human islet-derived progenitor cells
HLA Human leukocyte antigen
HNF Hepatocyte nuclear factor
hTERT Human telomerase reverse transcriptase
ICA Islet cell-like aggregates
IDO Indoleamime 2,3-dioxygenase
IDDM1 Insulin-dependent diabetes mellitus 1
IFN- Interferon gamma
IL Interleukin
IL2RA Interleukin 2 receptor subunit alpha
INS-FUR Furin-cleavable human insulin
IPCs Insulin-producing cells
IPGTT Intraperitoneal glucose tolerance test
iPSCs Induced pluripotent stem cells
IRES Internal ribosome entry site
ISG Insulin secretory granules
Isl-1 LIM Homeobox 1
IVC Individually ventilated cage
KCNJ11 ATP-sensitive potassium channel
LADA Latent-onset autoimmune diabetes in adults
LB Luria broth
LPK L-type pyruvate kinase
Luc2 Firefly luciferase
mAb Monoclonal antibody
MafA v-maf musculoaponeurotic fibrosarcoma A
MAP Mycobacterium avium paratuberculosis
MHC Major histocompatibility complex
MOI Multiplicity of infection
MODY Mature-onset diabetes of the young
MSCs Mesenchymal stem cells
NCBI National Centre for Biotechnology Information
NeuroD1 Neuronal differentiation 1
Neurog3 Neurogenin 3
NK Natural killer
Nkx2.2 NK2 homeobox 2
Nkx6.1 NK6 homeobox 1
P/S/G Penicillin-Streptomycin-Glutamine
PANDER Pancreatic derived factor
Pax4 Paired homeobox 4
Pax6 Paired homeobox 6
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PGE2 Prostaglandin E2
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PPAR- Peroxisome proliferator-activated receptor gamma
PTPN2 Protein tyrosine phosphatase, non-receptor type 2
PTPN22 Protein tyrosine phosphatase, non-receptor type 22
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RLU Relative light units
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rSAP Shrimp alkaline phosphatase
RT-PCR Reverse transcription polymerase chain reaction
SCA-1 Stem cell antigen 1
Scid Severe combined immunodeficiency
SSEA-1 Stage-specific embryonic antigen 1
STRO-1 Stromal cell antigen 1
STZ Streptozotocin
SV40T Simian virus 40 antigen
T1D Type 1 diabetes
T2D Type 2 diabetes
TBE Tris/Borate/EDTA
TCF7L2 Transcription factor 7-like 2
TFF Tangential flow filtration
TGF- Transforming growth factor beta
UC-MSCs Umbilical cord mesenchymal stem cells
UPRT Yeast uracil phosphoribosyltransferase pro-drug converting enzyme
UTR Untranslated region
VNTR Variable number tandem repeat
VSMCs Vascular smooth muscle cells
